These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 35897915)
21. Can Antimalarial Phytochemicals be a Possible Cure for COVID-19? Molecular Docking Studies of Some Phytochemicals to SARS-CoV-2 3C-like Protease. Hasan A; Jannat K; Bondhon TA; Jahan R; Hossan MS; de Lourdes Pereira M; Nissapatorn V; Wiart C; Rahmatullah M Infect Disord Drug Targets; 2022; 22(1):e290721195143. PubMed ID: 34376138 [TBL] [Abstract][Full Text] [Related]
22. Interaction of Laurusides 1 and 2 with the 3C-like Protease (M Autiero I; Roviello GN Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982585 [No Abstract] [Full Text] [Related]
23. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2. Abdizadeh R; Hadizadeh F; Abdizadeh T Mol Divers; 2022 Apr; 26(2):1053-1076. PubMed ID: 34213728 [TBL] [Abstract][Full Text] [Related]
24. Molecular modelling investigation for drugs and nutraceuticals against protease of SARS-CoV-2. Kodchakorn K; Poovorawan Y; Suwannakarn K; Kongtawelert P J Mol Graph Model; 2020 Dec; 101():107717. PubMed ID: 32861974 [TBL] [Abstract][Full Text] [Related]
25. Repositioning of anti-dengue compounds against SARS-CoV-2 as viral polyprotein processing inhibitor. Bajrai LH; Faizo AA; Alkhaldy AA; Dwivedi VD; Azhar EI PLoS One; 2022; 17(11):e0277328. PubMed ID: 36383621 [TBL] [Abstract][Full Text] [Related]
26. A Study of Drug Repurposing to Identify SARS-CoV-2 Main Protease (3CLpro) Inhibitors. Jo S; Signorile L; Kim S; Kim MS; Huertas O; Insa R; Reig N; Shin DH Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742913 [TBL] [Abstract][Full Text] [Related]
27. Molecular Binding Mechanism and Pharmacology Comparative Analysis of Noscapine for Repurposing against SARS-CoV-2 Protease. Kumar N; Sood D; van der Spek PJ; Sharma HS; Chandra R J Proteome Res; 2020 Nov; 19(11):4678-4689. PubMed ID: 32786685 [TBL] [Abstract][Full Text] [Related]
28. Some Flavolignans as Potent Sars-Cov-2 Inhibitors Cetin A Curr Comput Aided Drug Des; 2022; 18(5):337-346. PubMed ID: 35975852 [TBL] [Abstract][Full Text] [Related]
29. An Updated Review on SARS-CoV-2 Main Proteinase (M Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134 [TBL] [Abstract][Full Text] [Related]
30. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease. Akaji K; Konno H Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349 [TBL] [Abstract][Full Text] [Related]
31. Discovery of M Protease Inhibitors Encoded by SARS-CoV-2. Hung HC; Ke YY; Huang SY; Huang PN; Kung YA; Chang TY; Yen KJ; Peng TT; Chang SE; Huang CT; Tsai YR; Wu SH; Lee SJ; Lin JH; Liu BS; Sung WC; Shih SR; Chen CT; Hsu JT Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32669265 [TBL] [Abstract][Full Text] [Related]
32. Discovery of potent inhibitors for SARS-CoV-2's main protease by ligand-based/structure-based virtual screening, MD simulations, and binding energy calculations. Abu-Saleh AAA; Awad IE; Yadav A; Poirier RA Phys Chem Chem Phys; 2020 Oct; 22(40):23099-23106. PubMed ID: 33025993 [TBL] [Abstract][Full Text] [Related]
33. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV. Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605 [TBL] [Abstract][Full Text] [Related]
34. Polarizable MD and QM/MM investigation of acrylamide-based leads to target the main protease of SARS-CoV-2. Nochebuena J; Cisneros GA J Chem Phys; 2022 Nov; 157(18):185101. PubMed ID: 36379777 [TBL] [Abstract][Full Text] [Related]
35. Depicting the inhibitory potential of polyphenols from Ghosh R; Chakraborty A; Biswas A; Chowdhuri S J Biomol Struct Dyn; 2022 Jun; 40(9):4110-4121. PubMed ID: 33292085 [TBL] [Abstract][Full Text] [Related]
37. In silico study of alkaloids with quercetin nucleus for inhibition of SARS-CoV-2 protease and receptor cell protease. Mohebbi A; Eskandarzadeh M; Zangi H; Fatehi M PLoS One; 2024; 19(4):e0298201. PubMed ID: 38626042 [TBL] [Abstract][Full Text] [Related]
38. Coagulation modifiers targeting SARS-CoV-2 main protease Mpro for COVID-19 treatment: an in silico approach. Biembengut ÍV; de Souza TACB Mem Inst Oswaldo Cruz; 2020; 115():e200179. PubMed ID: 32490889 [TBL] [Abstract][Full Text] [Related]